VIS 513
Alternative Names: VIS-513Latest Information Update: 19 Aug 2024
At a glance
- Originator Duke-NUS Graduate Medical School Singapore; Massachusetts Institute of Technology
- Developer Serum Institute of India; Visterra
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dengue
Most Recent Events
- 19 Aug 2024 Oxford University Clinical Research plans a phase II trial for Dengue (In children, In adolescents, In adults, In the elderly) in Vietnam in September 2025 (IV) (NCT06551844)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Dengue in USA (Parenteral)
- 27 Sep 2022 Phase-II clinical trials in Dengue in India (Parenteral) (Visterra website, September 2022)